Navigation Links
B cell receptor inhibitor causes chronic lymphocytic leukemia remission
Date:12/11/2011

SAN DIEGO - A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology.

"PCI-32765, one of a new class of experimental drugs called B cell receptor inhibitors, has shown impressive potential in this clinical trial for its effectiveness and particularly for its relatively minimal toxicity," said lead investigator Susan O'Brien, M.D., professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

According to the National Cancer Institute's Surveillance Epidemiology and End Results database, an estimated 14,570 people will receive a diagnosis of CLL in 2011 and about 4,380 patients will die of the disease.

Six-month progression free survival of 90-92 percent

Of 27 CLL patients treated at a dose of 420 milligrams daily, 70 percent had complete or partial remission at 10.2 months of median follow-up. Six-month progression-free survival was 92 percent. Patients received a median three prior treatments before entering the clinical trial.

At a higher dose of 840 mg, 44 percent of 34 patients achieved complete or partial remission at 6.5 months median follow-up, similar to the response rate of the lower-dose cohort at 6.2 months. Progression free survival at 6 months was 90 percent. Study participants had received a median of five prior treatments.

Overall, five patients (8 percent) of the 61 from both arms had progressive disease and 50 (82 percent) remained on the therapy.

Drug does not suppress blood cell production

CLL presently is treated with combination chemotherapies that can cause myelosuppression - inhibited bone marrow function leading to decreased production of blood cells. The resulting susceptibility to infection can be a problem for patients, O'Brien said.

"PCI-32765 is not myelosuppressive. The main side effect is mild diarrhea that is usually self-limiting," O'Brien said.

Chronic lymphocytic leukemia is caused by overproduction of defective B cell lymphocytes, white blood cells that fight infection by producing antibodies.

PCI-32765 is orally administered and inhibits the Burton's tyrosine kinas (BT) enzyme, which is central to B cell receptor signaling. The drug causes programmed cell death and hinders cell migration and adhesion in malignant B cells.

A Phase III clinical trial is planned. The clinical trial was funded by Pharmacyclics, Inc., the drug's developer.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Toll-like receptors play role in brain damage in newborns
2. Folate receptors may serve as a front door to ovarian cancer treatment
3. Nuclear receptors battle it out during metamorphosis in new fruit fly model
4. Cell receptor could allow measles virus to target tumors
5. CSHL structural biologists reveal novel drug binding site in NMDA receptor subunit
6. Historic first images of rod photoreceptors in the living human eye
7. Older age memory loss tied to stress hormone receptor in brain
8. Entire T-cell receptor repertoire sequenced revealing extensive and unshared diversity
9. Researchers get a grip on nervous systems receptors
10. Feast or famine: Researchers identify leptin receptors sidekick as a target for appetite regulation
11. Targeting nicotine receptors to treat cognitive impairments in schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Cambridge, MA (PRWEB) , ... February 09, 2016 ... ... Institute (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for ... medical services covered in the report, Evaluation of the 2015 Fee Schedule ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... announces today the continuation of the ‘Pay It Forward’ program into 2016. BioPlus ... received at our specialty pharmacy. , “Since our Pay It Forward program ...
(Date:2/9/2016)... , ... February 10, 2016 , ... The Journal ... need to “level the playing field .” , As corresponding author Dr John F. ... use to categorize and diagnose our chronic pain patients. ‘Chronic cancer pain’ and ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... to expand access to affordable hearing aids , increase industry transparency, and ... in the United States. , “For the average consumer, the hearing aid industry ...
(Date:2/9/2016)... ... 2016 , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter ... June 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of ... in 2015, the Maui Photo Expedition workshop will once again consist of ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016 The leader in accelerated orthodontics, OrthoAccel ... is the recipient of the 2015 Townie Choice Award ... II medical device that speeds up orthodontic tooth movement ... often associated with treatment, AcceleDent was selected by orthodontists ... Orthotown survey of the most reliable and ...
(Date:2/9/2016)... NEW BRUNSWICK, N.J. , Feb. 9, 2016 /PRNewswire/ ... in the RBC Capital Markets Global Healthcare Conference on ... New York City.  Dominic Caruso , Vice President, ... , Worldwide Chairman, Consumer will represent the Company in ... www.investor.jnj.com . --> www.investor.jnj.com . ...
(Date:2/9/2016)... Md. , Feb. 9, 2016  The ... for pharmaceutical professionals developing and manufacturing sterile drug ... Sterile Manufacturing Regulatory Guidance Comparison – With link ... guidance documents issued by the U.S. FDA, the ... Health Organization. --> ...
Breaking Medicine Technology: